date:Jun 01, 2012
The 12-week study, announced last week at Digestive Disease Week in San Diego, California, showed improvements in a double blind, placebo controlled trial involving 186 patients with moderate to severe IBS.
The Symprove trial is a real breakthrough for IBS sufferers, as we now have robust evidence of a treatment that can reduce the severity of a range of IBS symptoms,said lead researcher, professor Ingvar Bjarnason, from Kings College.
The 18-65 year old patients were either given Symprove o